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BACKGROUND. Adenosquamous carcinoma of the lung is composed of adenocar-
cinomatous and squamous cell carcinomatous components. The epidermal
growth factor receptor (EGFR) mutations occur mostly in adenocarcinomas and
rarely in squamous cell carcinoma of lung. Attempts to investigate the EGFR
mutation status in each component of adenosquamous carcinoma and to charac-
terize the patients according to mutation status may help to understand the his-
togenesis of adenosquamous carcinoma.
METHODS. The mutation status of EGFR kinase domain from exon 18 to 21 was
investigated in 25 Korean patients with adenosquamous carcinoma by polymer-
ase chain reaction–single strand conformation polymorphism using the tissues of
each component from the adenosquamous carcinoma tumor. Clinicopathologic
characteristics of the patients according to the status of EGFR mutations were
compared.
RESULTS. EGFR mutations were identified in 11 (44%) patients: 9 mutations were
in exon 19, 1 in exon 20, and 1 in exon 21. EGFR mutations were significantly
more frequent (P ¼ .005) in women (n ¼ 8, 80%) than men (n ¼ 3, 20%). Never-
smokers (n ¼ 8, 62%) had EGFR mutations more commonly than smokers
(n ¼ 3, 25%; P ¼ .111). Identical EGFR mutations in both components of adeno-
squamous carcinoma were confirmed by nucleotide sequencing.
CONCLUSIONS. The frequency of EGFR mutation and clinicopathologic character-
istics of the EGFR mutants in adenosquamous carcinoma are similar to those of
Asian patients with adenocarcinomas. Identical EGFR mutations in both compo-
nents suggest the possibility of monoclonality in the histogenesis of adenosqua-
mous carcinoma. Cancer 2007;109:581–7.  2006 American Cancer Society.
KEYWORDS: epidermal growth factor receptor, mutation, carcinoma, adenosqua-
mous.
A denosquamous carcinoma is a rare subtype of nonsmall-celllung cancer (NSCLC), detected in 0.4% to 4% of lung cancer.1 A
notable feature of adenosquamous carcinoma is the heterogeneous
nature of the tumors. According to the World Health Organization’s
histologic classification of lung tumors, adenosquamous carcinoma
is defined as a carcinoma showing components of both squamous
cell carcinoma and adenocarcinoma, with each comprising at least
10% of the whole tumor.1 Because phenotypically different 2 types
of NSCLC exist in a tumor, 2 different clonal pathways, monoclo-
nality and polyclonality, have been proposed for the histogenesis of
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adenosquamous carcinoma. Monoclonality consists of
a transformation from 1 component to the other, and
the polyclonality results from the collision of 2 tumors.2
The epidermal growth factor receptor (EGFR) is a
transmembrane receptor with tyrosine kinase activ-
ity. NSCLC frequently expresses EGFR.3–6 Ligand
binding to the extracellular domain induces EGFR
homo- or heterodimerization, activation of tyrosine
kinase activity, autophosphorylation to tyrosine resi-
dues, and intracellular signal transduction that leads
to cellular proliferation, angiogenesis, metastasis,
and inhibition of apoptosis.7 Somatic gain-of-func-
tion mutations in exons encoding the EGFR tyrosine
kinase domain have been identified in NSCLC,8,9 and
subsequent studies revealed that EGFR mutation
could be the responsive marker to the tyrosine kinase
inhibitors gefitinib and erlotinib.10–12 Interestingly,
EGFR mutations occur more frequently in a subset
of patients with NSCLC. Adenocarcinoma, women,
never-smokers, and Asians are well-known clinico-
pathologic characteristics of EGFR mutants.8–10,13–16
On the contrary, EGFR mutations in squamous cell
carcinomas of the lung are very rare.10,11,17–19 There-
fore, investigation of EGFR mutation status in the
adenocarcinomatous and squamous cell carcinoma-
tous components separated from individual adeno-
squamous carcinoma would elucidate whether the
occurrence of EGFR mutations is histology-specific.
This result may help to understand the histogenesis
of adenosquamous carcinoma, especially in clonality.
Genetic alterations, chromosomal abnormalities,
and immunohistochemical reactions in both compo-
nents of adenosquamous carcinomas were compared
in few studies, which suggested the possibility of
monoclonality and similar biological characteristics
of both components.20–23 Using DNA flow cytometry
analysis, Ichinose et al.20 showed a relation between
both components in 8 (67%) out of 12 adenosqua-
mous carcinomas. Identical monoclonal pattern in
both components of all four cases were shown using
clonal analysis of X chromosome.21 The same p53
overexpression and p53 mutation, similar loss of het-
erozygosity at 9p21 and 9q31-32, and no K-ras muta-
tion in both components of 12 adenosquamous
carcinoma cases were also reported.22 Recently,
Toyooka et al.23 reported that 3 (27%) of 11 adeno-
squamous carcinoma had EGFR mutations, 2 muta-
tions in exon 19 and 1 in exon 21, and they were
identical in each component. They used a laser cap-
ture microdissection or manual microdissection for
the separation of each component. It was the first
report of EGFR mutations in the cohort of adeno-
squamous carcinomas. However, further investigation
with a larger sample size is required to clarify the
genetic and clinicopathologic characteristics of the
patients with adenosquamous carcinomas.
Owing to the poor prognosis of patients with
adenosquamous carcinoma,24–29 other therapeutic
strategies to improve patient outcome are needed.
Recent studies proved that EGFR mutations are
associated with response and survival in patients
with NSCLC treated with tyrosine kinase inhibitor
(TKI).8–10,12–14,16,30,31 The status of EGFR mutations
would provide evidence as to whether TKIs could be
therapeutic options in adenosquamous carcinoma.
We separated each component from adenosqua-
mous carcinoma to investigate the status of EGFR
mutation separately and then compared the results
of 1 component with the other. To characterize pa-
tients according to the status of EGFR mutations, we
correlated EGFR mutation status with clinicopatho-
logic characteristics of the patients.
MATERIALS AND METHODS
Patients and Tissues
One thousand and ten patients underwent surgical
resection for the treatment of NSCLC between Octo-
ber 1994 and May 2004 at Severance Hospital, Seoul,
Korea. Twenty-eight cases with adenosquamous car-
cinoma (2.8% of NSCLC) during that period were
selected from the database of our institution. Among
them, tissue samples were available in 25 cases
(Table 1). All cases were reevaluated by 2 patholo-
gists (D.W.S. and H.K.). Formalin-fixed paraffin-em-
bedded tissues of 10 mm thickness were used to
extract genomic DNA. Adenocarcinomatous and squa-
mous cell carcinomatous components from each
tumor were separated precisely by manual microdis-
section under microscopic observation to avoid con-
tamination of each sample from different components.
To enrich the tumor cell population, areas containing
more than 90% of tumor cells were sampled from
hematoxylin–eosin-stained slides. Grossly normal tis-
sue remote from the tumor was included as a control
and judged to be benign. Clinical data were obtained
from the medical record team. Never-smoker was
defined as an individual having no lifetime smoking
history. The study protocol was reviewed and approved
by the Institutional Review Board of Yonsei University
College of Medicine, Seoul, Korea.
EGFR Gene Analysis
Genomic DNA from the separate components was
prepared using the sodium dodecyl sulfate-protein-
ase K and phenol-chloroform extraction method.
Somatic mutations in exons 18 to 21 of EGFR were
detected using a polymerase chain reaction (PCR)-based
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assay as described previously.32,33 The primer sets
were as follows (forward and reverse, respectively):
exon 18, (50-AGCTTGTGGAGCCTCTTACAC-30 and 50-
CCACCAGACCATGAGAGG-30), exon 19 (50-ATGTGG-
CACCATCTCACAAT–30 and 50-CCACACAGCAAAGCA-
GAAAC–30); exon 20 (20-1, 50-CACACTGA-CGTGCCT-
CTCC-30 and 50-GTCTTTGTGTTCCCGGACAT-30; 20-2,
50-AGCTCATCACGCAGCTCAT-30 and 50-TTATCTCC-
CCTCCCCGTATC-30), and exon 21 (50-CCTCACAGCA-
GGGTCTTCTC–30 and 50-CACCTCCTTACTTTGCCT-
CCT–30). PCR was carried out with a 20 mL mixture
containing 1.5 mM MgCl2; 20 pmol of primer;
0.2 mM each of dATP, dGTP, and dTTP; 5 mM dCTP;
1 mCi of [a-32P] dCTP (3000 Ci/mmol; DuPont New
England Nuclear, Boston, MA); 50 ng of sample DNA;
1 PCR buffer; and 1.25 units of Taq DNA polymer-
ase (Life Technologies, Grand Island, NY). After dena-
turation at 958C for 5 minutes, DNA amplification
was performed for 30 cycles. This consisted of dena-
turation at 958C for 30 seconds, primer annealing at
558C for 30 seconds, and elongation at 728C for 15
seconds. PCR products were separated on 0.5
mutation detection enhancement (MDE, CAMBREX
Bioscience, Rockland, ME) gels, followed by autoradi-
ography for single-strand conformation polymorph-
ism (SSCP) analysis. Shifted bands were cut from gel,
resuspended in distilled water, resubjected to PCR,
and then sequenced with an ABI Prism 310 Genetic
Analyzer (Applied Biosystems, Foster City, Calif) in
both forward and reverse strand directions.
Statistical Analysis
The association between EGFR mutation and clinico-
pathologic variables were assessed using x2, Fisher
exact tests, or t-test. The SPSS statistical software
package (v. 11.5, SPSS, Chicago, Ill) was used for all
calculations. Two-sided P-values < .05 were consid-
ered significant.
RESULTS
Molecular Characteristics in EGFR Mutations
Eleven (44%) out of 25 cases showed shifted bands
on PCR-SSCP analysis. Each component from a tu-
mor displayed the same patterns of shifted band.
Nucleotide sequencing the extracted PCR product of
a shifted band confirmed the presence of EGFR
mutations in these cases. Interestingly, adenocarcino-
matous and squamous cell carcinomatous compo-
nents of adenosquamous carcinomas with EGFR
mutations carried identical EGFR mutations (Fig. 1).
Results of the mutational analysis were as follows
(Table 2): 9 mutations were in exon 19, 1 in exon 20,
and 1 in exon 21. Four types of in-frame deletions
were observed: 5 were simple deletions (del E746-
A750), 2 were coupled with insertion (del E746-A750,
ins IP), 1 with substitution (del L747-E749, A750P),
and 1 with duplication/insertion and substitution
(indel; del T751-I759, dup/ins EAREA). ‘‘indel; del
T751-I759, dup/ins EAREA’’ is a novel mutation
found in this study. It resulted from the deletion of
nucleotides 2257–2276, duplication or insertion of
2243–2249 at the deleted site, and substitution
2277C?G. ‘‘ins D770-G771’’ is another novel muta-
tion found in exon 20. The nucleotide of 2308 was a
common point of insertion in exon 20, but insertion
of ACGGCG at this point has never been described
before. All the mutations occurred as single muta-
tions in individual samples.
Correlations of EGFR Mutations With
Clinicopathologic Characteristics
EGFR mutations were significantly more frequent in
women (80%) than in men (20%; P ¼ .005) (Table 3).
Never-smokers (62%) had EGFR mutations more
commonly than smokers (25%), but there was no sta-
tistic significance (P ¼ .111). All the female patients
with EGFR mutations were never-smokers. The clas-
sification of histologic subtypes in this study was
based on histologic characteristics of the adenocarci-
TABLE 1
Baseline Patient Characteristics
























BAC indicates bronchioloalveolar carcinoma.
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nomatous component only. The acinar component
was observed in all the patients, except 1 with solid
subtype. Four patients showing a solid component in
their tumors had no EGFR mutations. All mixed sub-
types of the EGFR mutant were a mixture of acinar
and bronchioloalveolar carcinoma (BAC) subtypes.
The occurrence of the EGFR mutation according to
the presence or absence of BAC components did not
differ (P ¼ .389).
DISCUSSION
Adenosquamous carcinomas comprised 2.8% of 1010
NSCLC patients treated by surgical resections. This
frequency is similar to that of the previous
reports.25,27,29,34 In the present study we detected
EGFR mutations in 11 (44%) of 25 Korean adeno-
squamous carcinoma patients. Also, we found that
both components of adenosquamous carcinoma,
adenocarcinomatous and squamous cell carcinoma-
tous component, carried identical EGFR mutations.
We demonstrated that adenosquamous carci-
noma was another subtype of NSCLC that frequently
harbors EGFR mutations (44%), which was compara-
ble to the frequency observed in Asian patients
with adenocarcinomas.9,13,14,16,17,35,36 EGFR muta-
tions have been found mostly in adenocarcinomas.
On the contrary, the frequency of EGFR mutation in
squamous cell carcinoma of the lung is very low.
Only 8 cases (1.1%) out of 732 of squamous cell
carcinomas had EGFR mutations in our review
of published reports.10,11,13–15,17–19,30,35 The clinical
characteristics of EGFR mutants of adenosquamous
carcinoma patients were similar to those of adeno-
carcinomas, but not squamous cell carcinomas.
Asian ethnicity, adenocarcinoma histology, female
and never-smoker are well-known clinicopathologic
characteristics of patients with EGFR mutations in
NSCLC.8–10,13–16 High frequency, female predomi-
nance, and never-smoking status of EGFR mutations
in Korean patients with adenosquamous carcinoma
FIGURE 1. Single-strand conformation polymorphisms and electropherograms demonstrating identical EGFR mutations in ADC and SCC. (A) in-frame deletion
with insertion (del E746-A750, ins IP) in exon 19. (B) amino acid substitution (L858R) in exon 21. The sites of deletion (black and white inverted triangles) and
substitution (line) are shown. N, normal tissue; ADC, adenocarcinomatous component; SCC, squamous cell carcinomatous component.
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were similar features observed in adenocarcinomas.
Thus, we found that common characteristics were
associated with the occurrence of EGFR mutations in
patients with adenocarcinomatous histology in their
tumors. About half of patients who were smokers in
our study did not correspond to the previous studies,
which reported that about 80% of patients with ade-
nosquamous carcinomas were smokers.25,34 Although
higher responses to TKI in individuals with adeno-
carcinomas with BAC features have been reported,37
the association between the presence of EGFR muta-
tions and BAC components of adenocarcinomas was
unclear. In some studies, EGFR mutations were
observed more commonly in adenocarcinomas with
BAC features.15,35 However, no association between
the presence of EGFR mutation and BAC features in
adenocarcinomas was reported in other studies.16,36
In our study with adenosquamous carcinomas, there
was no association between features of BAC histology
in adenocarcinomatous components and the pre-
sence of EGFR mutations. There was no relation
between EGFR mutations and pathologic stage, as
described in previous reports with NSCLC.14–17,35 It is
unusual that most of EGFR mutations (82%) occurred
in exon 19 because mutation in exon 21 is as com-
mon as in exon 19. A study showed that in-frame
deletions in exon 19 accounted for 44% of all EGFR
mutations and missense mutation in exon 21 for
41% of lung cancer.38 Because SSCP is more sensitive
than direct sequencing to detect EGFR mutations,
especially point mutations,15 it is unlikely to miss a
mutation in exon 21 in our samples.
Identical EGFR mutations, despite distinct phe-
notypic differences between adenocarcinomatous and
squamous cell carcinomatous components, were de-
tected simultaneously in both components of a tu-
mor in this study. It was not only an interesting
finding, but could be the clue to the clonal pathway
of adenosquamous carcinoma because the occur-
rence of EGFR mutations in squamous cell histology
was very rare. In addition to frequent mutations in the
squamous cell component, collision of both compo-
nents with identical EGFR mutations seemed very
unlikely to happen. Therefore, we thought that a mono-
clonal pathway that each component of adenosqua-
mous carcinoma originated from common progenitor
cells was more probable than a polyclonal pathway in
the histogenesis of adenosquamous carcinoma.
Patients with adenosquamous carcinoma have
been reported to have a poor prognosis.24–27,29 In a
TABLE 2
Mutations in EGFR
Sex Age Smoking Exon Nucleotide changes Amino acid changes
W 40 Never 19 2235_2249del del E746-A750
W 64 Never 19 2235_2249del del E746-A750
W 44 Never 19 2235_2249del del E746-A750
W 57 Never 19 2235_2249del del E746-A750
W 72 Never 19 2235_2249del del E746-A750
W 72 Never 19 2239_2247del, 2248G>C del L747-E749, A750P
M 63 Smoker 19 2235_2236del, 2242_2248del, 2241A>C del E746-A750, ins IP
W 52 Never 19 2235_2236del, 2242_2248del, 2241A>C del E746-A750, ins IP
W 61 Never 19 2252_2276del, 2243_2249dup/ins, 2277C>G indel; del T751-I759, dup/ins EAREA
M 48 Smoker 20 2308insACGGCG ins D770-G771
M 57 Smoker 21 2573T>G L858R
TABLE 3
Comparison of Clinicopathologic Characteristics With
EGFR Mutations
Epidermal growth factor receptor gene
P
Mutant (n = 11) Wild type (n = 14)
No. % No. %
Age, y .207
Median 57 64
Range 40 – 72 49 – 72
Sex .005
Men 3 20 12 80
Women 8 80 2 20
Smoking .111
Never 8 62 5 38
Smoker 3 25 9 75
Histologic type .827
Acinar 6 43 8 57
Solid 0 0 1 100
Mixed 5 50 5 50
BAC components .389
Yes 5 63 3 37
No 6 35 11 65
Stage .238
I, II 4 31 9 69
III 7 58 5 42
BAC indicates bronchioloalveolar carcinoma.
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series of studies including more than 40 cases, 5-year
postoperative survival rates of patients with adeno-
squamous carcinoma ranged from 18.5% to 36.7%,
which were lower than patients with either adenocar-
cinomas or squamous cell carcinomas.24,25,28,29 Stage,
peripheral location, visceral pleural involvement, and
component predominance are the factors associ-
ated with poor prognosis in adenosquamous carci-
noma.25,28 Shigematsu et al.16 reported no relation
between EGFR mutation status and patient survival
in the absence of EGFR kinase inhibitor therapy.
However, patients with deletions in exon 19 had
worse survival, with borderline significance, than
those with L858R missense mutation in exon 21, and
those without EGFR mutations. Considering the pre-
dominance of deletional types in EGFR mutation in
adenosquamous carcinoma patients, the specific type
of EGFR mutation, deletion in exon 19, could be
another factor associated with the poor prognosis.
Because of the low incidence and difficulties in diag-
nosing adenosquamous carcinoma, data available on
EGFR mutation status in adenosquamous carcinoma
were very limited. Seven cases of adenosquamous car-
cinoma showing EGFR mutations have been re-
ported.13,14,18,23,31 Among them, a male patient with a
recurring large chest-wall mass showed a dramatic
response to gefitinib.31 Therefore, trial with TKI that tar-
gets both components of adenosquamous carcinoma
would be a reasonable therapeutic option to adeno-
squamous carcinoma patients with EGFR mutations.
Surgical resection is required for the diagnosis of
adenosquamous carcinoma due to its histologic heter-
ogeneity. It is impossible to diagnose adenosquamous
carcinoma with certainty in small biopsy specimens
obtained by transbronchial biopsy because they can-
not represent all the histologic characteristics of ade-
nosquamous carcinoma. If histologic diagnosis of
squamous cell carcinoma is made on a bronchoscopic
or transbronchial biopsy specimen, and the specimen
is found to have EGFR mutation, one could consider
the possibility of adenosquamous carcinoma.
In conclusion, the frequency of the EGFR muta-
tion and clinicopathologic characteristics of the EGFR
mutants of adenosquamous carcinoma are similar to
those of Asian patients with adenocarcinomas. Identi-
cal EGFR mutations in both adenocarcinomatous and
squamous cell carcinomatous components suggest
the possibility of monoclonality in the histogenesis of
adenosquamous carcinoma.
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